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DBackground: Aortic valve replacement in patients with aortic stenosis is usually followed by regression of left
ventricular hypertrophy. More complete resolution of left ventricular hypertrophy is suggested to be associated
with superior clinical outcomes; however, its translational impact on long-term survival after aortic valve
replacement has not been investigated.
Methods: Demographic, operative, and clinical data were obtained retrospectively through case note review.
Transthoracic echocardiography was used to measure left ventricular mass preoperatively and at annual
follow-up visits. Patients were classified according to their reduction in left ventricular mass at 1 year after
the operation: group 1, less than 25 g; group 2, 25 to 150 g; and group 3, more than 150 g. Kaplan–Meier
and multivariable Cox regression were used.
Results:A total of 147 patients were discharged from the hospital after aortic valve replacement for aortic stenosis
between1991 and 2001. Preoperative left ventricularmasswas 279 98g ingroup1 (n¼ 47), 347 104g ingroup
2 (n¼ 62), and 491 183 g in group 3 (n¼ 38) (P<.001). Mean time to last echocardiogramwas 6.2 3.2 years.
Left ventricularmass at late follow-upwas 310 119 g in group 1, 267 107 g in group 2, and 259 96 g in group
3 (P¼ .05). Transvalvular gradients at follow-upwere not significantly different among the groups (group 1, 24.8
23 mmHg; group 2, 21.4 16 mmHg; group 3, 14.7 9 mmHg) (P¼ .31). Therewas no difference in the prev-
alence of other factors influencing left ventricular mass regression such as ischemic heart disease or hypertension,
valve type, or valve size used. Ten-year actuarial survival was not statistically different in patients with enhanced
left ventricularmass regressionwhen comparedwith the log–rank test (group 1, 51% 9%; group 2, 54% 8%;
and group 3, 72%  10%) (P ¼ .26). After adjustment, left ventricular mass reduction of more than 150 g was
demonstrated as an independent predictor of improved long-term survival on multivariate analysis (P ¼ .02).
Conclusions: Our study is the first to suggest that enhanced postoperative left ventricular mass regression, spe-
cifically in patients undergoing aortic valve replacement for aortic stenosis, may be associated with improved
long-term survival. In view of these findings, strategies purported to be associated with superior left ventricular
mass regression should be considered when undertaking aortic valve replacement. (J Thorac Cardiovasc Surg
2011;142:285-91)Aortic valve stenosis (AS) subjects the left ventricle to abnor-
mal loading conditions leading to the development of left
ventricular hypertrophy (LVH).1 A principal aim of the sur-
gical treatment of aortic valve lesions is to restore normal
left ventricular (LV) hemodynamics.2 Aortic valve replace-
ment (AVR) is usually followed by regression of LVH.3,4
This is considered to be advantageous and potentially to be
associated with improved clinical outcomes.5 However, thee Department of Cardiothoracic Surgery, Royal Brompton Hospital, London,
d Kingdom.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Aug 9, 2009; revisions received July 29, 2010; accepted for
cation Aug 31, 2010; available ahead of print Jan 27, 2011.
for reprints: Ayyaz Ali, MRCS, Department of Cardiothoracic Surgery,
l Brompton Hospital, London, SW3 3NP, United Kingdom (E-mail:
75@gmail.com).
23/$36.00
ht 2011 Published by Elsevier Inc. on behalf of The American Association
racic Surgery
016/j.jtcvs.2010.08.084
The Journal of Thoracic and Capresumed correlation between left ventricular mass (LVM)
regression and impaired long-term outcome is based on ex-
trapolation from historical studies, which documented the
negative impact of LVH on survival in patients with hyper-
tensive heart disease.6-9 Ventricular hypertrophy secondary
to aortic valve disease is a distinct entity from that which
occurs in response to essential hypertension.10Consequently,
presumptions that hypertrophy in these 2 settings will have
an equivalent effect on outcome are unfounded. The impact
of persistent LVH on long-term clinical outcomes, specifi-
cally in a population of patients who have undergone AVR
for significant AS, has not been previously investigated.
Our aim was to evaluate whether enhanced LVM regression
after AVR is correlated with improved long-term survival.METHODS
This is a retrospective review of a consecutive series of patients who
underwent AVR with a stentless bioprosthesis for aortic valve diseaserdiovascular Surgery c Volume 142, Number 2 285
Abbreviations and Acronyms
AS ¼ aortic valve stenosis
AVR ¼ aortic valve replacement
LV ¼ left ventricular
LVH ¼ left ventricular hypertrophy
LVM ¼ left ventricular mass
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Dfrom January 1991 to January 2001. Patients were not excluded from
analysis if they had additional concomitant cardiac procedures.
Bioprosthetic Stentless AVR
The Toronto Stentless Porcine Valve (St Jude Medical, Inc, St Paul,
Minn) was the stentless valve used in this series. Allograft valves were
also used. An established allograft cryopreservation protocol has been in
place at our institution for over 15 years.
Surgical Technique
Operations were performed by a single surgeon (J.P.) The decision to
use a biological valve and type of valve selected was left to surgeon–patient
preference. In general, allografts were used for redo procedures and in
patients of younger age. All procedures were performed with the patient
supported by cardiopulmonary bypass with cooling to 28C. Myocardial
protection was undertaken with antegrade and retrograde cold blood cardi-
oplegia. The majority of bioprostheses were implanted in the subcoronary
position. With allograft valves, the coronary sinuses were excised but the
noncoronary sinus was preserved. The valve was then implanted with sep-
arate inflow and outflow suture lines. Interrupted sutures were used for the
proximal suture line and continuous for the distal anastomosis. Separate
mattress sutures were used to secure the commissures. Allograft valves
were also implanted as a free-standing root replacement with reimplanta-
tion of the native coronary artery ostia as buttons within the allograft wall.
Data Acquisition
Demographic, clinical, and operative data were obtained from individ-
ual patient hospital records. Our follow-up protocol included annual echo-
cardiograms to assess cardiac and allograft valve function. Serial
echocardiographic reports were reviewed to document LVM. Mortality
was determined using the NHS strategic tracing system (NHS, United
Kingdom) and survivors were contacted by telephone for interview. Ap-
proval for this study was obtained from Royal Brompton and Harefield
and Imperial College Ethics Committee (Ethics number 00-128).
Echocardiographic Details
Patients in our series had annual echocardiographic follow-up at our
institution. Transthoracic echocardiography was performed with the
Hewlett–Packard Sonos 5000 echocardiograph (Hewlett–Packard, Houston,
Tex). Two-dimensional images were obtained with standard apical 5-
chamber, parasternal short- and long-axis views. Continuous wave Doppler
was used tomeasure transvalvular gradients. LVMwasmeasured by 2 expe-
rienced echocardiographers in all patients before and afterAVR.LVvolumes
in cubic centimeters were measured from apical 4-chamber views using the
Simpson rule. In patients in whom the Simpson rule could not be used, the
area–length method was used. LVM was then calculated using values
obtained for the external (EDVe) and internal (EDVi) end-diastolic volume
using the following equation: LVM ¼ 1.05 (EDVeEDVi) g.
Clinical Definitions and Follow-up Protocol
Hypertension was defined as a systolic blood pressure greater than
140 mm Hg or a diastolic blood pressure greater than 90 mm Hg. Poor286 The Journal of Thoracic and Cardiovascular SurgLV function was defined as an LV ejection fraction of less than or equal
to 30%, documented on either left ventriculography or transthoracic echo-
cardiography. The end points of interest were the following: postoperative
change in LVM at 1 year of follow-up and actuarial freedom from death.
Clinical follow-up data were collected in the immediate postoperative pe-
riod and subsequently during annual clinic visits. All surviving patients re-
mained on this annual surveillance protocol. The survival commenced at
the time of first year and ended at the time of death-event or at last
follow-up (censoring).The selection of the time point of 1 year postopera-
tively was considered as being more clinically important in informing us
about patient prognosis. All patients were included on an intention-
to-treat basis; thus all attempted procedures, including initial technical
procedure failures, were included in the overall analysis.
Statistical Methods
Patients were classified according to their reduction in LVM at 1 year of
follow-up: group 1, less than 25 g or increase in LVM from baseline;
group 2, 25 to 150 g; group 3, more than 150 g. Data were expressed as
mean  standard deviation for normally distributed values and median 
interquartile change when variables were not normally distributed. Normal
distribution of each continuous variable was assessed with the Kolmo-
gorov–Smirnov test, and for comparison, analysis of covariance with
Bonferroni correction for normally distributed variables was used. For
the nonnormally distributed variables, the Kruskal–Wallis test was used
to compare groups, and the cutoff value for significance was adjusted for
multiple comparison to the value of .01. Categorical variables were shown
as percentages. Comparisons for categorical variables were performed with
the c2 test.
Actuarial outcomeswere compared with Kaplan–Meier curves andmul-
tivariable Cox proportional hazards regression. A log–rank test was used to
determinewhether significant differences existed between curves. The pro-
portional hazard assumption was tested for each covariate by 2 methods:
first, correlating the corresponding Scaled Schoenfeld Residuals with the
rank of time; second, using the procedure ‘‘stphtest’’ in Stata (Stata Corpo-
ration, College Station, Tex). The linearity assumption for each binary co-
variate was assessed graphically with Martingale residuals. To elucidate
associated causative factors to the outcomes of interest, we performed
a multivariable regression analysis. Initially, univariable regression analy-
sis was used to determine all significant confounding variables (covariates).
Those associated confounding variables were subsequently included in the
multivariable regression model. Statistically (P  0.2) or clinically signif-
icant causative factors from the univariable analysis were adjusted for (in-
cluded) in the multivariable model. We also included those variables that
were found to have a different distribution among the 3 LVM regression
groups and we thought may have been able to influence results. All statis-
tical tests were 2-sided. In all cases, corrections were not made for multiple
comparisons. Statistical analysis was performed using SPSS 17.0 (SPSS
Inc, Chicago, Ill) and Stata 9.0 (Stata Corporation).RESULTS
Between January 1, 1991, and January 1, 2001, 153 pa-
tients underwent AVR with a homograft or stentless porcine
valve. There were 6 (3.9%) postoperative deaths. One hun-
dred forty-seven patients who survived AVR underwent
postoperative echocardiography at 1 year to assess the ex-
tent of LVM regression. Forty-seven patients had less than
25 g of LVM regression at late follow-up (group 1), in 62
patients LVM regression was between 25 and 150 g (group
2), and in 38 patients LVM regression was greater than
150 g. Patient characteristics according to extent of LVM
regression are listed in Table 1.ery c August 2011
TABLE 1. Baseline characteristics
Degree of LVM
regression
Group 1:
<25 g
Group 2:
25–150 g
Group 3:
>150 g
P
value
No. 47 (32) 62 (42) 38 (26)
Age  70 y 21 (45) 28 (45) 15 (40) .84
Female sex, n (%) 15 (32) 18 (29) 12 (32) .92
Hypercholesterolemia,
n (%)
10 (21) 8 (13) 6 (16) .51
Diabetes, n (%) 5 (11) 3 (5) 2 (5) .45
Hypertension, n (%) 17 (36) 24 (39) 15 (41) .92
Serum creatinine
 150 mmol/L
2 (4) 0 (0) 3 (8) .09
Antihypertensive
treatment (ACE
inhibitor)
15 (32) 22 (37) 14 (39) .77
Sinus rhythm 40 (85) 56 (90) 32 (84) .60
Valve size  25 mm 22 (47) 31 (50) 19 (50) .94
Redo AVR 5 (11) 4 (7) 3 (8) .73
Operative urgency
Emergency, n (%) 6 (13) 5 (8) 3 (8) .66
LV function
LVEF  30%, n (%) 7 (15) 7 (11) 3 (2) .60
Preoperative functional
status
Pre NYHA class III/IV,
n (%)
27 (57) 31 (50) 20 (53) .74
Preop echocardiography
LVEDD, cm (SD) 4.8 (0.97) 5.3 (0.87) 5.8 (1.1) <.001
LVESD, cm (SD) 3.3 (1.1) 3.5 (0.90) 3.76 (0.88) .10
LVEF,% (SD) 65 (18) 69 (15) 70 (13) .24
Transaortic gradient,
mm Hg (SD)
69 (24) 74 (21) 71 (13) .54
LVM, g (SD) 279 (98) 347 (104) 491 (183) <.001
LVM, Left ventricular mass; ACE, angiotensin-converting enzyme; AVR, aortic valve
replacement; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA,New
York Heart Association; LVEDD, left ventricular end-diastolic dimension; SD, stan-
dard deviation; LVESD, left ventricular end-systolic dimension.
TABLE 2. Operative characteristics and postoperative outcomes
Degree of LVM
regression
Group 1:
<25 g
Group 2:
25–150 g
Group 3:
>150 g
P
value
No. 47 (32) 62 (42) 38 (26)
Concomitant CABG,
n (%)
18 (38) 19 (31) 7 (19) .16
No. of grafts, n (SD) 0.53 (0.8) 0.53 (0.9) 0.35 (0.8) .56
Valve type and insertion
Homograft, n (%) 22 (47) 28 (45) 17 (45) .98
Valve size, mm (SD) 24.5 (2.6) 24.5 (2.2) 24.8 (2.7) .75
Subcoronary implant,
n (%)
42 (89) 56 (90) 32 (84) .63
Postoperative functional
status
Postop NYHA class
III/IV, n (%)
3 (6) 0 (0) 1 (3) .13
Postoperative
pacemaker
1 (2) 2 (3) 8 (22) .001
Clinical outcomes
Anticoagulation, n (%) 3 (6.4) 5 (8) 3 (8) .54
Thromboembolism,
n (%)
0 (0) 2 (3) 1 (3) .42
Endocarditis, n (%) 1 (2) 1 (2) 0 (0) .71
Postop echocardiography
(last follow-up)
LVEDD, cm (SD) 5.21 (1.1) 4.95 (0.81) 4.67 (0.6) .07
LVESD, cm (SD) 3.47 3.24 2.95 .06
LVEF,% (SD) 72.4 (13) 71 (12) 72 (11) .89
Transaortic gradient,
mm Hg (SD)
24.8 (23) 21.4 (16) 14.7 (9) .31
LVM, g (SD) 310 (119) 267 (107) 259 (96) .05
CABG, coronary artery bypass grafting; SD, standard deviation; NYHA, New York
Heart Association; LVEDD, left ventricular end-diastolic dimension; LVESD, left
ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LVM,
left ventricular mass.
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The mean age of our study population was 65 12 years,
consisting of 102 (70%) men. Therewere no differences be-
tween groups with regard to age or sex. Seventy-eight
(53%) patients were in New York Heart Association func-
tional class III/IV preoperatively. In total, 147 patients
were operated on for aortic stenosis. Fourteen (10%) pa-
tients underwent emergency surgery. Twelve (8%) patients
in the series were undergoing redo AVR.Preoperative Echocardiography
Details relating to preoperative echocardiographic mea-
surements are listed in Table 1. Patients in group 3 had sig-
nificantly larger LVend-diastolic diameter (P<.001). There
was no difference between groups in end-systolic dimen-
sions, LV ejection fraction, or preoperative transvalvular
gradient. LVM was also significantly higher in group 3
patients at baseline (P<.001).The Journal of Thoracic and CaOperative Details
Operative and postoperative data are documented in
Table 2. Allograft valves were implanted in 67 (46%) pa-
tients. The Toronto Stentless Porcine Valve was implanted
in the subcoronary position in 80 (54%) patients. The bio-
prostheses were implanted using the subcoronary freehand
technique in 130 (88%). Seventeen (12%) patients who had
an allograft implanted received a freestanding root replace-
ment with reimplantation of the coronary ostia. The mean
valve size implanted was 24.6 (2.5) mm with no differences
in size among the 3 LVM regression groups. There was no
difference among groups in the frequency of concomitant
coronary artery bypass grafting or mean number of bypass
grafts performed per patient.Postoperative Echocardiography
Postoperative echocardiographic details are listed in
Table 2. There were significant trends of differences in
LV end-diastolic diameter (P ¼ .07) and a trend for end-
systolic dimensions among groups (P ¼ .06). Mean timerdiovascular Surgery c Volume 142, Number 2 287
FIGURE 1. Changes in left ventricular end-diastolic diameter (LVEDD) (A), transvalvular gradient (B), and ejection fraction (EF) (C) during follow-up in
patients groups with different degree of left ventricular mass (LVM) regression The P value for the different LVM groups (vertical axis) has been calculated
by analysis of covariance and the P values for different time points (horizontal axis) are from the Bonferroni test.
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follow-up was 310 119 g in group 1, 267 107 g in group
2, and 259  96 g in group 3 (P ¼ .05). Transvalvular gra-
dients at follow-up were not significantly different among
groups (group 1, 24.8  23 mm Hg; group 2, 21.4 
16 mm Hg; group 3: 14.7  9 mm Hg; P ¼ .31). Two
patients in group 1, 2 in group 2, and 1 in group 3 demon-
strated an increased transvalvular gradient of more than
50 mm Hg, demonstrating degenerative disease of the288 The Journal of Thoracic and Cardiovascular Surgreplaced valve during follow-up. Changes in LV end-
diastolic diameter, transvalvular gradients, and LV ejection
fraction during follow-up for the 3 groups of patients are
depicted in Figure 1. Patients in group 3 had smaller LV
end-diastolic dimensions and lower postoperative trans-
valvular gradients, although this did not reach statistical sig-
nificance. Between 1 year and late follow-up, there was
a significant increase in transvalvular gradient in all groups
(P value from Bonferroni test, P ¼ .01).ery c August 2011
FIGURE 2. Actuarial survival according to left ventricular mass (LVM)
reduction at 1 year of follow-up.
TABLE 3. Predictors of late mortality in univariable analysis
P value
Age  70 y <.001
Concomitant CABG <.001
Sub-coronary technique .005
Homograft valve .01
Antihypertensive treatment (ACE inhibitor) .03
Postop NYHA class III/IV .03
Preop NYHA class III/IV .05
Valve size  25 mm .06
Preop LVM .08
Emergency operation .12
Hypertension .21
LVEF  30% .23
Diabetes .26
Redo AVR .34
Serum creatinine  150 mmol/L .50
Sex (male) .59
Permanent pacemaker .87
Hypercholesterolemia .91
Loss of sinus rhythm .93
CABG, Coronary artery bypass grafting; ACE, angiotensin-converting enzyme;
NYHA, New York Heart Association; LVM, left ventricular mass; LVEF, left ventric-
ular ejection fraction; AVR, aortic valve replacement.
TABLE 4. Independent predictors of late mortality on multivariable
analysis
Sig. Exp(B)
95.0% CI for Exp(B)
Lower Upper
Age  70 y .003 2.81 1.41 5.59
Postop NYHA class III/IV .000 62.84 12.10 326.24
Concomitant CABG .003 2.64 1.39 5.00
Preop LVM .036 1.00 1.000 1.01
Preop NYHA class III/IV .11 1.70 0.87 3.29
Subcoronary implantation .09 6.59 0.71 61.05
Homograft valve .24 0.60 0.25 1.410
Serum creatinine  150 mmol/L .25 2.48 0.52 11.81
Antihypertensive treatment
(ACE inhibitor)
.26 1.43 0.76 2.70
Emergency operation .43 1.43 0.58 3.53
Postoperative pacemaker .64 1.29 0.42 3.97
Valve size  25 mm .84 0.92 0.42 1.99
LVM<25 g (reference: group 1) 1.00
LVM 25–150 g (group 2) .19 0.61 0.294 1.286
LVM>150 g (group 3) .02 0.28 0.09 0.87
Sig., Significance; Exp(B), exponentiation of the B coefficient; CI, confidence inter-
val; NYHA, New York Heart Association; CABG, coronary artery bypass grafting;
LVM, left ventricular mass; ACE, angiotensin-converting enzyme.
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Themean time to follow-upwas 7.8 (3.1) years. Five-year
(group 1, 89%  5%; group 2, 93%  3%; group 3, 94%
 4%) and 10-year (group 1, 51% 9%; group 2, 54%
8%; group 3, 72%  10%) actuarial survivals were not
significantly greater in patients with enhanced LVM regres-
sion: log–rank ¼ 2.68; df ¼ 2; P ¼ . 26 (Figure 2).
Cox Hazard Regression Analysis
The results of univariable analysis are presented in Table
3. Cox proportional hazard survival regression analysis was
undertaken to identify independent predictors of late mor-
tality, and results are presented in Table 4. Independent pre-
dictors of late mortality were identified as the following:
age 70 years or older (P ¼ .003), preoperative LVM
(P<.03), postoperative New York Heart Association class
III/IV (P<.001), and concomitant coronary artery bypass
grafting (P< .003). LVM regression greater than 150 g
was independently protective against late mortality with
a hazard ratio of 0.28 (0.09–0.87)
DISCUSSION
In this retrospective study we investigated whether supe-
rior LVM regression after AVR in patients with AS was as-
sociated with improved long-term survival. Through
analysis of serial echocardiograms, we determined the ex-
tent of LVM regression after the first year of follow-up
and assessed whether this had an association with late prog-
nosis. Patients with enhanced LVM regression (>150 g) did
not demonstrate improved survival on Kaplan–Meier anal-
ysis compared with thosewith less resolution of LVH. How-
ever, after adjustment for other confounders, multivariable
Cox regression analysis demonstrated that the magnitudeThe Journal of Thoracic and Caof LVM regression was an independent predictor of im-
proved long-term survival.
Concentric LVH develops in patients with AS or systemic
hypertension and represents adaptation of LV muscle to ex-
cessive intraventricular pressure. Such changes in the shape
of the left ventricle allow it to maintain a normal relation be-
tween systolic wall stress and ejection fraction. Population
studies have identified that LVH is associated with anrdiovascular Surgery c Volume 142, Number 2 289
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and congestive heart failure.6,7,9 Accordingly, LVH is
linked to impaired long-term survival compared with
age-matched controls.7,8 Previous studies evaluating the
impact of incomplete regression of ventricular
hypertrophy on surgical outcome have been limited by
small numbers of patients and a short duration of follow-
up.11,12 There are minimal data on the impact of
persistent LVH on very long-term survival specifically after
AVR in patients with AS. A lack of such information has led
to extrapolations being made from the observational studies
discussed herein. The consensus has been that residual LVH
after AVR has a detrimental effect on long-term survival,5,13
although some investigators have reported contradictory
findings.14 LVH in the setting of AS has been correlated
with a number of adverse effects including abnormal
coronary flow reserve and exacerbation of diastolic dys-
function.15,16 Consequently, cardiac surgeons and valve
manufacturers have concentrated their efforts toward
engineering prostheses with optimal hemodynamic
performance to facilitate postoperative LVM regression.
LVH is the culmination of a variety ofmolecular processes
in response to chronic pressure overload. It is associatedwith
geometric chamber alterations, changes in ventricular mass,
as well as myocardial cellular structure and development of
fibrosis.17 Differences exist in the morphometry of hypertro-
phy associated with essential hypertension and AS. Strot-
mann and associates10 used strain-rate imaging studies of
LV long- and short-axis function to demonstrate that despite
similar degrees of LV wall thickness, AS and arterial hyper-
tension had different effects on the rate of LV deformation.
Consequently, the effect of LVH on outcomes in patients
with hypertension cannot be justifiably applied to patients
who have been surgically treated for aortic valve disease.
In our study, we observed that superior LVM regression
may have an independent effect on long-term survival after
AVR for AS. We classified patients according to the degree
of LVM regression that was observed at 1 year of follow-
up. Forty-seven patients lost less than 25 g of their LVmuscle
mass; survival was poorest in this group, with a 10-year
actuarial survival of only 51%  9%. Interestingly, the
LVM preoperatively was in fact lower than the follow-up
value in this group (preoperativevalue 279 g vs postoperative
value 310 g), with this subset of patients demonstrating an
increase in LVM. Sixty-two patients had regression of be-
tween 25 and 150 g over follow-up and 38 had a reduction
of greater than 150 g. Both of these patient groups were
observed to have a net loss of LVM over the long term and
had greater survival at 10 years: 54%  8% and 72% 
10%, respectively.
Numerous variables have been suggested to influence
postoperative LVM regression. Recent studies have identi-
fied preoperative LVM as the most important determinant
of postoperative LVM regression,18,19 with patients with290 The Journal of Thoracic and Cardiovascular Surga larger preoperative LVM demonstrating the greatest
degree of LVM reduction. Other factors such as the type
and size of valve implanted, hypertension, residual
transaortic gradients, and the presence of ischemic heart
disease are thought to have an impact on resolution of
LVH. In accordance with these previous reports,
preoperative LVM was higher in our study in the group of
patients who demonstrated the greatest postoperative
reduction in LVM.8,19 There were no significant differences
between groups in the frequency of coexistent hypertension
or the type and size of valve used. The need for
concomitant coronary artery bypass grafting was not
different between groups. Enhanced LVM regression was
also associated with trends of significantly smaller LV end-
diastolic dimensions and end-systolic diameter. This sug-
gests that enhancedLVMregressionmay occur in association
with improved LV remodeling after AVR. Transvalvular gra-
dients were lower in group 3, and this may explain the pres-
ence of superior resolution of LVH in this group. This may
validate the use of strategies aimed at optimizing valvular he-
modynamics to promote LVM regression over the longer
term. Reduced LVM regression may be secondary to
a specific phenotype of LVH and may not necessarily be sec-
ondary to an inferior hemodynamic environment after AVR.
The reasons why LVM regression occurs in some individ-
uals and is incomplete in others, despite similar preopera-
tive values of LVM and postoperative hemodynamic and
clinical profiles, is uncertain. The presence of increased
amounts of myocardial fibrosis has been suggested as one
possible factor responsible for this observation.20 The mo-
lecular basis of LVM regression after AVR is being eluci-
dated. Walther and associates21 used an animal model to
study the role of changes in the cardiac extracellular matrix.
In a sheep model they observed that LVH induced by aortic
banding was associated with a significant increase in extra-
cellular matrix gene expression of matrix metalloprotei-
nases and a number of their tissue inhibitors. Regression
of these genes was noted after relief from chronic pressure
overload in their model.21 Further investigation is necessary
to scrutinize the molecular mechanisms responsible for
postoperative LVM regression after AVR. In particular, ef-
forts should be directed at understanding why some subsets
of patients fail to demonstrate satisfactory LVM regression
despite adequate relief of AS and whether specific clinical
interventions in this group may be of value in promoting
resolution of LVH.
The advent and subsequent evolution of surgical treat-
ment for aortic valve disease has been accompanied by
a progressive drive toward engineering prostheses with op-
timal hemodynamic performance. A major impetus behind
these efforts has been the desire to facilitate remodeling of
the left ventricle after AVR, principally through resolution
of LVH. More recently, this has been invigorated by
concerns regarding the generation of patient–prosthesisery c August 2011
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stances in which a prosthesis is deemed to be too small
for a given patient, resulting in a degree of residual imped-
ance to transaortic flow This entity has been strongly linked
with both morbidity and mortality in patients undergoing
AVR.5,22 One of the major concerns relating to patient–
prosthesis mismatch is that it predisposes to incomplete
postoperative regression of LVH.5 We have demonstrated
that patients who have greater LVM regression after AVR
may exhibit increased survival at very long-term follow-
up. Furthermore, the group of patients who were observed
to have the greatest LVM regression was also found to
have lower postoperative tranvalvular gradients, although
this did not reach statistical significance. A number of strat-
egies can be used to avoid the development of patient–
prosthesis mismatch. The use of stentless valves, which
are engineered to occupy the smallest possible area within
the aortic root, is widely regarded as a means of maximizing
the available cross-sectional area for transprosthetic flow.
Procedures aimed at enlarging the aortic root represent an
alternative method aimed at avoiding patient–prosthesis
mismatch and maximizing the size of prosthesis that can
be implanted. A number of randomized trials have been un-
dertaken to compare performance of stentless valves with
the presumably more hemodynamically ‘‘challenged’’
stented valve. The results have been conflicting, with
some demonstrating improved hemodynamic performance
and LVM regression after stentless AVR,23 while others
have failed to identify any difference in such outcomes.24
One important conclusion that can be drawn from these
studies is that both stented and stentless AVR can be under-
taken with minimal morbidity and mortality. Similarly, con-
comitant aortic root enlargement procedures at the time of
AVR can also be performed with a low risk to patients.25
Evidence that superior LVM regression is correlated with
greater long-term survival warrants that interventions
optimizing hemodynamic performance be used to promote
resolution of LVH.CONCLUSIONS
Enhanced LVM regression at late follow-up in patients
undergoing AVR is associated with improved long-term
survival. Strategies to optimize postoperative LVM regres-
sion should be considered in view of potential prognostic
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